

	IN T	HE UNI	TED STATES D	DT01 ESIGNATED/ELECTI	10/518924 Rec'd PCT/PTO 23 DEC 2004 ED OFFICE
				PCT/EP2003/00	
Internatio				19 May 2003 (1	9.05.2003)
Internation	onal Fili	ng Date	:	24 June 2002 (2	
Priority I	Date(s)	Claimed	:		
Applicar	nt(s) (Do	O/EO/US) :	Hiltrud LINDE	
Title: I	JQUID	PREPAF	RATION COMPR	USING OLIGOPEPTIDI	
INFOR	MATI	ON DISC	CLOSURE STAT	EMENT UNDER 37 C	FR §§ 1.56, 1.97 and 1.98
Commi	ssioner	for Patent	ts		
Sir:	This in 98 as fo	formatior llows:	n disclosure staten	nent is made in accordance	e with 37 C.F.R. §§ 1.56, 1.97
<u>Timin</u>	g and Fo	<u>ees</u>			a c Sing this information
\boxtimes	Under disclo	sure state	ment is filed.		ed for filing this information
		within t	hree months of th 1.53(d);	e filing date of a national	application other than a CPA
	\boxtimes	within	three months of tion; OR		the national phase of a PCT
		before	the mailing of a fi		ion (including after filing of an
	Und spec	er 37 C.F. ified in 3	R. § 1.97(c), this i 7 C.F.R. § 1.97(b)	information disclosure stands of the mailing of the mailing	atement is filed after the periods date of:
			a final rejection	under 37 C.F.R. 1.113;	
			OR		e Quayle, M.P.E.P § 609(B)(2);
		П	a notice of allo	wance under 37 C.F.R. §	1.311; and
				1	MED CK - 2955



	is acco	mpanied by:	DIOT REC'D PUT/ME	2 3 DEC 20
	П		C.F.R. § 1.97(e) set out below;	OR
			30.00 under 37 C.F.R. § 1.17(p).	
Under date o	37 C.F		sclosure statement is filed after the	e mailing
		a final action under 37 C.F.R.		
		termination of prosecution, e.g	g. Ex Parte Quayle, M.P.E.P § 6	09(B)(2);
<u>.</u>		a notice of allowance under 3'	7 C.F.R. § 1.311;	•
AND	is filed	l on or before payment of the iss	ue fee; AND is accompanied by	:
		the statement as specified in 3 the fee of \$180.00 under 37 C	37 C.F.R. § 1.97(e) as set forth b	elow, and
Statements I	Under 3	7 C.F.R. 1.97(e)		
		Each item of information statement was cited in a com	contained in this information munication from a foreign patent on having a mailing date not more e of this information disclosure st	e than three
		was cited in a communication foreign application, and to after making reasonable inqu	nined in this information disclosur in from a foreign patent office in a the knowledge of the undersign uiry, no item of information conta ment was known to any individua than three months prior to the fi- statement.	ed attorney ained in this I designated
Cited Mate	<u>erials</u>			ra a 6 120)
	an 14	cestor application Serial No49 by the applicant; see 37 C.F.I		
\boxtimes	re	port dated August 28, 2003.	attached were cited in an interna	
] C	opies of the materials listed are a	attached (except for the foregoin	g).



Non-English Language References
An English-language search report or equivalent paper and a landing area of the cited reference(s).
A foreign-language search report from a foreign patent office is provided and a provided the provided and a substantively below:
X = document of particular relevance when it is taken alone $Y = $ document of particular relevance when it is combined with another such
document A = document defining the general state of the art O = non-written disclosure P = intercalated document the theory or principle underlying the
T = document cited to understand the filing date invention
and which was published only
L = cited for another reason a = publication of member of same patent family
Souther relevant information on foreign search report
In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das of formula, "Beispele" means examples, and "Spalte" ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, means claims, "Anspruch" means example, and "Tabellen" means summary, and "Tabelle" means "In der Anmeldung table, and "Tabellen" means tables "in der Anmeldung table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other Information
Payment of Fees Due (If Any): A check for \$ covering the fee identified above is attached.
Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose. \boxtimes

Respectfully submitted,

Anthony //Zelano, Reg. No. 27,969

Attorney Agent for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2955

Date: December 23, 2004

AJZ:ssr



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	a required to respond to a collection of information
Under the Paperwork Reduction Act of 1995, no persons are	Complete if Known
Substitute for form 1449A/PTO	USNP of PCT/EP2003/005224
INFORMATION DISCLOSURE	Filing Date 19 May 2003 (19.05.2009)
STATEMENT BY APPLICANT	First Nameu invente.
STATEMENT BY ALLES	Group Art Unit
(use as many sheets as necessary)	Examiner Name
of 2	Attorney Docket Number MERCR-2933
Sheet	

U.S. Patent Document Kind Code ² Name of Patentee or Applicant of Cited Document MM-DD-YYYY	 		U.S. P	ATENT DOCUMENTS	Data of Bublication of Cited Document
	001	Number 6001961	ent Kind Code ²	Name of Patentee or Applicant of Cited Document GOODMAN ET AL.	12-14-1999

		F	oreign Patent Docur		Name of Patentee or Applicant of	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Examiner Initials*	Cite No.1	Office ³	Number ⁴	(if known)	Cited Document JANSSEN PHARMACEUTICAL	08-08-1991		
	003	wo	9111200	-	JANSSEN PHARMACEUTICAL	07-04-1985		
	004	wo	8502767 0062793		JONES ET AL.	10-26-2000		
	003	100						┼
		\						上

L					
Œ	xaminer			Date Considered	attation if not in conformance
Ls	ignature	L	per or not citation is in conf	formance with MPEF	P 609. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is place a check mark here if English language Corresponding family member. patent document. Nind of document by the appropriate symbols as indicated on the document under vvirO Standard 51. 16 if possible. to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box	Please type a plus sign (+) inside this	\rightarrow	+
---	---	---------------	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO USNP of PCT/EP2003/005224 Application Number INFORMATION DISCLOSURE 19 May 2003 (19.05.2003) Filing Date Hiltrud LINDENBLATT ET AL. STATEMENT BY APPLICANT First Named Inventor unknown Group Art Unit unknown Examiner Name (use as many sheets as necessary) MERCK-2955 Attorney Docket Number of

Aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, aminer Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the article (when appropriate), title of the articl			Sneet
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, article in the item (book, magazine, item). Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, item).	ENTS	NON PATENT LITERATURE DOCUM	1 480 K
KAMM, W. ET AL: "EVALUATION OF ABSORPTION EN MUMAN INTESTINAL CELL LINE(CACO- CYCLOPEPTIDIC.ALPHANUBETA.3-ANTAGONIST IN A HUMAN INTESTINAL CELL LINE(CACO- CYCLOPETIDIC.ALPHANUBETA.3-ANTAGONIST IN A HUMAN INTESTINAL CELL LINE(CACO- CYCLOPETIDIC.ALPHANUBETA.3-ANTAGONIST INTESTINAL CELL LINE(CACO- CYCLOPETIDIC.ALPHANUBETA.3-ANTAGONIST INTESTINAL CELL LINE(CACO- CYCLOPETIDIC.ALPHANUBETA.3-ANTAGONIST INTESTINAL CELL LINE(CACO- CYCLOPETIDIC.ALPHANUBETA.3-ANTAGONIST INTESTINAL CELL LIN	n appropriate), title of the item (book, magazine, (s), publisher, city and/or country where published. T ²	Include name of the author (in CAPITAL LETTERS), title of the article (when	xaminer
	JMAN INTESTINAL CELL LINE(CACO-	KAMM, W. ET AL: "EVALUATION OF ABSORPTION EN IAMA CYCLOPEPTIDIC ALPHANUBETA.3-ANTAGONIST IN A HU CYCLOPEN JOURNAL OF PHARMACEUTICAL SCIENCES 2006 2)" EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES LINKE SPALTE LETZTER ABSATZ; SEITE 208, LINKE SPALT	Initials *

		Date	
Examiner	'	Considered	
Signature			son. Draw line through citation if not in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.